NCT03258567 2026-03-06Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomasNational Institutes of Health Clinical Center (CC)Phase 2 Recruiting40 enrolled